234 related articles for article (PubMed ID: 24842413)
1. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.
Yeh JM; Nohria A; Diller L
Ann Intern Med; 2014 May; 160(10):661-71. PubMed ID: 24842413
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.
Wong FL; Bhatia S; Landier W; Francisco L; Leisenring W; Hudson MM; Armstrong GT; Mertens A; Stovall M; Robison LL; Lyman GH; Lipshultz SE; Armenian SH
Ann Intern Med; 2014 May; 160(10):672-83. PubMed ID: 24842414
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer.
Ehrhardt MJ; Ward ZJ; Liu Q; Chaudhry A; Nohria A; Border W; Fulbright JM; Mulrooney DA; Oeffinger KC; Nathan PC; Leisenring WM; Constine LS; Gibson TM; Chow EJ; Howell RM; Robison LL; Armstrong GT; Hudson MM; Diller L; Yasui Y; Armenian SH; Yeh JM
J Clin Oncol; 2020 Nov; 38(33):3851-3862. PubMed ID: 32795226
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors.
Steingart RM; Liu JE; Oeffinger KC
Ann Intern Med; 2014 May; 160(10):731-2. PubMed ID: 24842420
[No Abstract] [Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
[TBL] [Abstract][Full Text] [Related]
7. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
Lipshultz SE; Lipsitz SR; Sallan SE; Simbre VC; Shaikh SL; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2002 Dec; 20(23):4517-22. PubMed ID: 12454107
[TBL] [Abstract][Full Text] [Related]
8. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
11. Health and economic benefits of increased beta-blocker use following myocardial infarction.
Phillips KA; Shlipak MG; Coxson P; Heidenreich PA; Hunink MG; Goldman PA; Williams LW; Weinstein MC; Goldman L
JAMA; 2000 Dec; 284(21):2748-54. PubMed ID: 11105180
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
14. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Anis AH; Sun H; Singh S; Woolcott J; Nosyk B; Brisson M
Pharmacoeconomics; 2006; 24(4):387-400. PubMed ID: 16605284
[TBL] [Abstract][Full Text] [Related]
15. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
Banka G; Heidenreich PA; Fonarow GC
J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan.
Inomata T; Izumi T; Kobayashi M
Circ J; 2004 Jan; 68(1):35-40. PubMed ID: 14695463
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.
Shekelle P; Morton S; Atkinson S; Suttorp M; Tu W; Heidenreich P; Gubens M; Maglione M; Jungvig L; Roth E; Newberry S
Evid Rep Technol Assess (Summ); 2003 Jul; (82):1-6. PubMed ID: 14571595
[No Abstract] [Full Text] [Related]
18. Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.
Watz R; Ekstrand AB; Engelbrektson V; Beermann B
Eur J Clin Pharmacol; 2005 May; 61(3):209-14. PubMed ID: 15761755
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of diagnostic strategies for patients with chest pain.
Kuntz KM; Fleischmann KE; Hunink MG; Douglas PS
Ann Intern Med; 1999 May; 130(9):709-18. PubMed ID: 10357689
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
Golan L; Birkmeyer JD; Welch HG
Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
